LATEST NEWS

Brazilian Regulatory System – News Roundup

Date: 10/24/2019

Our team has compiled a few important news from the past days concerning medical device’s regulation and the Brazilian regulatory system:

ANATEL – New regulation for Conformity Assessment and Homologation of Telecommunication Products

ANATEL approved on October 17th, the new Regulations for Conformity Assessment and Homologation of Telecommunications Products.

The new Regulation institutes the end of fee charges for the homologation certificate’s issuance. The exemption from the fee is immediate and valid for all telecommunications products approved by ANATEL.

In the conformity assessment process, the equipment is subjected to verification of technical standards and laboratory tests that seek to ensure that they are properly tested and approved for use in Brazil.

The Regulations to which it refers shall enter into force within 180 days from the date of publication of the Resolution in the DOU (Brazilian Official Gazzete), except in relation to the obligations contained in Title IV and art. 58, concerning, respectively, the Market Surveillance Program and the exemption from the fees, which will enter into force on the date of publication of the new Resolution.

The changes, comparing it to the current regulation, concern the gratuity of the Homologation Fee, the Market Supervision Program, with the collection of samples made by the OCDs or ANATEL, and Certificates of Technical Compliance that will be issued only considering the applicant established regularly in the country.

Also, the Market Surveillance Program – where OCDS will collect samples directly from the market, according to procedure to be defined by ANATEL, came into effect with the publication. OCDs may also have Memorandum of Understanding with foreign Certification Bodies, as long as they are accredited by an accrediting Body recognized by INMETRO / ANATEL.

Petition Analysis Cycle Panel – ANVISA’s new online tool

ANVISA has recently made available on its website the Petition Analysis Cycle Panel, a tool that shows all the steps of the petition process, from the entry in the analysis queue to the moment the registrations and authorizations are finalized.

The purpose is to present, at various levels of analysis, the main stages and life cycle times of petition analysis.  With the aid of the new instrument, companies now have the opportunity to know the average and median deadlines for the granting of product registration and Business Operation Authorizations (AFEs).

ANVISA’s Webinar

ANVISA periodically hosts a Webinar – virtual seminars that bring updated content and knowledge to the public. This week, the Webinar addressed medical equipment’s registration main technical requirements. In addition, ANVISA presented the main reasons for medical equipment’s registration refusal and notification’s cancellation.

The purpose of the seminar was to explain the process of regularization of risk class I and II equipments according to Collegiate Board Resolution (RDC) 270/2019, RDC 40/2015 and Normative Instruction (IN) 22/2017, among other norms and understandings on the subject.

The recording of the seminar and comments made during the transmission are available in portuguese.

“20 years of Medical Device Regulation at ANVISA – next steps”

Registration is now open for participation in the Regulatory Dialogue “20 years of Medical Device Regulation at ANVISA – next steps”. The activity will be held next November 6, in Brasilia. The program of the event includes the discussion of topics such as advances and regulatory perspectives in the country, highlighting the challenges related to custom-made medical devices, software and product’s cybersecurity.

Follow us on social media to get an update on the top news regarding the Brazilian regulatory system.

DOMO Salute Team

 

MORE NEWS

07/18/2024
  From June 24 to 28, ANVISA participated in the MDSAP Forum and Regulatory Authority Council (RAC) meeting in Essen, Germany. The event gathered representatives from 27 countries, including regulatory authorities, MDSAP auditing organizations, and industry representatives, with notable attendance from Brazilian associations ABIMED and [...]
07/02/2024
  In force since January 2022, RDC 591/2021, which provides for the Unique Device Identification (UDI) system, was amended by ANVISA just days before the deadline for attributing and affixing UDI to risk class IV devices. The amendment was published in RDC 884/2024 on June 1, 2024, and is already in force. According to ANVISA,... Leia [...]
04/12/2024
Marking a significant advancement in regulatory reliance mechanisms, the National Health Surveillance Agency (ANVISA) published Normative Instruction (IN) 290/2024, on April 8, 2024. This normative introduces an optimized procedure for evaluating and deciding on registration petitions for medical devices previously regulated in recognized [...]
03/22/2024
Important Regulatory Update for Manufacturers under MDSAP in Brazil Today, ANVISA has announced a significant regulatory development with the publication of Resolution RDC 850/2024. This regulation brings forth a crucial amendment concerning the validity period of the Brazilian Good Manufacturing Practices (BGMP) Certificate for manufacturers [...]
01/05/2024
Collegiate Board Resolution (RDC) 837/2023, published by ANVISA on December 15th, 2023, brings updates to the rules regarding clinical investigations with medical devices performed in Brazil. Effective immediately from the publication, this resolution aligns Brazilian practices with international standards, providing clearer guidelines for [...]
12/13/2023
On 11 of December 2023, ANVISA published Collegiate Board Resolution – RDC 830/2023, addressing risk classification, registration procedures, as well as labeling requirements and instructions for use of in vitro diagnostic medical devices (IVDs) in Brazil. The new RDC, effective from June 1, 2024, is a comprehensive revision that consolidates [...]
11/28/2023
Public Consultation No. 1.208 will be open to receive contributions until December 9th. In the dynamic landscape of medical device regulations in Brazil, obtaining the Brazilian Good Manufacturing Practices (BGMP) certification is a mandatory request for manufacturers of Class III and Class IV devices seeking Registro. In a recent move towards [...]
03/01/2023
  Starting today – March 1st 2023 – the new Resolution RDC nº 751/2022  comes into force. The Resolution provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use. In order to meet the new requirements and procedures, ANVISA has already [...]
09/22/2022
The Collegiate Board Resolution – RDC 751/2022 was published on the 21st of September 2022, which provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use. The new RDC consolidates the risk classification and regularization regimes for all risk [...]